Thyroid : official journal of the American Thyroid Association · 2026
Shorter Versus Standard Antithyroid Drug Therapy in Graves' Disease with Lower Baseline Thyrotropin Receptor Antibody (TRAb) Levels: Relapse Outcomes from a Propensity-Weighted Analysis.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Razvi Salman, Holley Mia, Wheeler Hannah, Vernazza Jonathan, Stewart Kathryn, Pearce Simon H S, Narayanan Kilimangalam, Tsatlidis Vasileios
Аннотация
BACKGROUND: The optimal duration of antithyroid drug (ATD) therapy in Graves' disease is uncertain. Although guidelines recommend 12-18 months, shorter courses may be sufficient in selected patients. We evaluated whether ATD duration <12 months is non-inferior to 12-18 months for relapse among patients with Graves' disease and lower thyrotropin receptor antibody (TRAb) levels (>1.8 and <10.0 U/L) at diagnosis.
METHODS: We analyzed real-world data from adults with Graves' disease and baseline TRAb <10 U/L treated with ATDs at a single center. The primary endpoint was relapse within 12 months of ATD cessation. A prespecified risk-difference non-inferiority framework was used, with a primary margin of +5% and an exploratory margin of +10%. Treatment effects were estimated using unadjusted analyses, inverse-probability-of-treatment weighting (IPTW; n = 369), and 1:1 propensity-score matching (PSM; 104 matched pairs). Secondary outcomes included long-term relapse (median follow-up 58 months), TRAb levels at cessation, and restricted mean survival time (RMST) over 60 months.
FINDINGS: At 12 months, relapse occurred in 23/134 (17.2%) patients treated <12 months and 48/235 (20.4%) treated for 12-18 months. The IPTW-adjusted risk difference was -1.5% (CI -11.0 to +8.0), meeting the 10% but not the 5% non-inferiority margin. The unadjusted estimate (-3.2%) met both margins, whereas the PSM estimate (+2.9%, CI -7.3 to +13.1) met neither because of reduced precision. Long-term outcomes were similar between groups (IPTW Cox HR 0.92 [CI 0.65-1.31]; RMST difference +3.2 months over 60 months [-2.1 to +8.4]). TRAb levels at cessation were comparable.
CONCLUSIONS: Among patients with Graves' disease and lower TRAb levels, shorter ATD courses (<12 months) produced outcomes broadly comparable to 12-18 months. Although strict non-inferiority was not confirmed at a 5% margin, findings meeting an exploratory 10% threshold support TRAb-guided individualization of ATD duration and justify prospective randomized evaluation.
METHODS: We analyzed real-world data from adults with Graves' disease and baseline TRAb <10 U/L treated with ATDs at a single center. The primary endpoint was relapse within 12 months of ATD cessation. A prespecified risk-difference non-inferiority framework was used, with a primary margin of +5% and an exploratory margin of +10%. Treatment effects were estimated using unadjusted analyses, inverse-probability-of-treatment weighting (IPTW; n = 369), and 1:1 propensity-score matching (PSM; 104 matched pairs). Secondary outcomes included long-term relapse (median follow-up 58 months), TRAb levels at cessation, and restricted mean survival time (RMST) over 60 months.
FINDINGS: At 12 months, relapse occurred in 23/134 (17.2%) patients treated <12 months and 48/235 (20.4%) treated for 12-18 months. The IPTW-adjusted risk difference was -1.5% (CI -11.0 to +8.0), meeting the 10% but not the 5% non-inferiority margin. The unadjusted estimate (-3.2%) met both margins, whereas the PSM estimate (+2.9%, CI -7.3 to +13.1) met neither because of reduced precision. Long-term outcomes were similar between groups (IPTW Cox HR 0.92 [CI 0.65-1.31]; RMST difference +3.2 months over 60 months [-2.1 to +8.4]). TRAb levels at cessation were comparable.
CONCLUSIONS: Among patients with Graves' disease and lower TRAb levels, shorter ATD courses (<12 months) produced outcomes broadly comparable to 12-18 months. Although strict non-inferiority was not confirmed at a 5% margin, findings meeting an exploratory 10% threshold support TRAb-guided individualization of ATD duration and justify prospective randomized evaluation.